Sanofi and Regeneron said today they will appeal a federal judge's ban on U.S. sales of Praluent in a patent case with Amgen.

Allergan today offered up a preview for 2017, projecting mid-single-digit percentage growth for net revenue and double-digit growth in earnings per share.

​​​​​​​How long does it take to lose $96 billion in market value? If you’re the three worst-performing major pharmas, only one year.

Alexion has wrapped up its Soliris sales fraud investigation, finding that senior management pressured employees in order to bump up quarterly revenue.

Eli Lilly's answer to rival Novo Nordisk's price-increase promises? A similar—though somewhat less potent—pledge. 

Short seller Andrew Left sent Express Scripts shares reeling Thursday afternoon by invoking the wrath of President-elect Donald Trump.

German drugmaker Boehringer Ingelheim has eliminated more than 240 jobs in the U.S. and is making cuts in Europe as well.  

New correspondence from the SEC shows it’s still got issues with Valeant's use of "non-GAAP" financial measures.

Leerink analysts think problems cited by the FDA for a Sanofi plant in France could spell issues for not one but two potential blockbusters under FDA review.